Generic Celebrex Availability

Celebrex is a brand name of celecoxib, approved by the FDA in the following formulation(s):

CELEBREX (celecoxib - capsule;oral)

  • Manufacturer: GD SEARLE
    Approval date: December 31, 1998
    Strength(s): 100MG, 200MG
  • Manufacturer: GD SEARLE
    Approval date: August 29, 2002
    Strength(s): 400MG [RLD]
  • Manufacturer: GD SEARLE
    Approval date: December 15, 2006
    Strength(s): 50MG

Has a generic version of Celebrex been approved?

No. There is currently no therapeutically equivalent version of Celebrex available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Celebrex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Substituted pyrazolyl benzenesulfonamides
    Patent 5,466,823
    Issued: November 14, 1995
    Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S.
    Assignee(s): G.D. Searle & Co.
    A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1## or a pharmaceutically-acceptable salt thereof.
    Patent expiration dates:
    • November 30, 2013
      ✓ 
      Drug substance
    • May 30, 2014
      ✓ 
      Pediatric exclusivity
  • Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
    Patent 5,563,165
    Issued: October 8, 1996
    Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S.
    Assignee(s): G. D. Searl & Co.
    A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I: ##STR1##
    Patent expiration dates:
    • November 30, 2013
      ✓ 
      Drug product
    • May 30, 2014
      ✓ 
      Pediatric exclusivity
  • Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
    Patent 5,760,068
    Issued: June 2, 1998
    Inventor(s): Talley; John J. & Penning; Thomas D. & Collins; Paul W. & Rogier, Jr.; Donald J. & Malecha; James W. & Miyashiro; Julie M. & Bertenshaw; Stephen R. & Khanna; Ish K. & Graneto; Matthew J. & Rogers; Roland S. & Carter; Jeffery S. & Docter; Stephen H. & Yu; Stella S.
    Assignee(s): G.D. Searle & Co.
    A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: ##STR1## or a pharmaceutically-acceptable salt thereof.
    Patent expiration dates:
    • June 2, 2015
      ✓ 
      Patent use: TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
    • December 2, 2015
      ✓ 
      Pediatric exclusivity
  • 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder
    Patent RE44048
    Issued: March 5, 2013
    Assignee(s): G.D. Searle LLC
    A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: or a pharmaceutically-acceptable salt thereof. A method of treating inflammation or an inflammation-associated disorder in a subject by administering a therapeutically-effective dose of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, or a pharmaceutically-acceptable salt thereof, to the subject.
    Patent expiration dates:
    • June 2, 2015
      ✓ 
      Patent use: TREATMENT OF PRIMARY DYSMENORRHEA
    • June 2, 2015
      ✓ 
      Patent use: TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
    • June 2, 2015
      ✓ 
      Patent use: TREATMENT OF ACUTE PAIN
    • June 2, 2015
      ✓ 
      Patent use: TREATMENT OF ANKYLOSING SPONDYLITIS
    • June 2, 2015
      ✓ 
      Patent use: TREATMENT OF OSTEOARTHRITIS
    • June 2, 2015
      ✓ 
      Patent use: TREATMENT OF RHEUMATOID ARTHRITIS
    • December 2, 2015
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Got questions about Rheumatoid Arthritis? Get answers from our expert Dr. Carteron. Click Here

Close
Hide
(web2)